TAS::75 0843::TAS HORMONE THERAPY AND COGNITIVE AGING IN OLDER AND YOUNGER POSTM

妇女健康倡议（WHI）激素治疗（HT）的随机临床试验旨在确定激素治疗是否对绝经后妇女的健康结果，特别是心血管健康有有益的影响。没有子宫的女性被随机分配每天服用一片含有共轭马雌激素（CEE） 0.625毫克（Premarin，惠氏制药公司）或相应安慰剂的药片，有子宫的女性被随机分配每天服用一片含有CEE 0.625毫克和醋酸羟孕酮（MPA） 2.5毫克（Prempro，惠氏制药公司）或相应安慰剂的药片。WHI记忆研究（WHIMS）是WHI的辅助研究，调查了HT对可能的痴呆和任何认知障碍风险的影响，以及随着时间的推移对整体认知变化的影响。联合治疗（2002年）和单独cee治疗（2004年）的WHI和辅助WHIMS研究比计划提前停止，因为这些治疗增加了健康风险，并不能预防冠心病。虽然研究药物已停用，但随访评估仍在继续。本合同的目的是继续对WHIMS认知健康结果流行病学（WHIMS- echo）队列中的妇女进行前瞻性随访，包括痴呆筛查和认知评估。该合同继续在最近发起的女性健康倡议记忆研究（WHIMS-Y）中进行前瞻性认知评估，以确定在WHI激素试验中随机分配到50-54岁的绝经后HT妇女的长期影响。WHIMS-Y测试了“机会之窗”假说，即绝经后不久的HT将对以后的认知健康有益。

The Women's Health Initiative (WHI) randomized clinical trials of hormone therapy (HT) were designed to determine whether HT had beneficial effects on health outcomes, especially cardiovascular health, in postmenopausal women. Women without uteri were randomly assigned to take one daily tablet containing either conjugated equine estrogens (CEE), 0.625 mg (Premarin, Wyeth Pharmaceuticals), or a matching placebo, and women with uteri were randomly assigned to take one daily tablet containing either CEE, 0.625 mg, and medroxy progesterone acetate (MPA), 2.5 mg, (Prempro, Wyeth Pharmaceuticals) or a matching placebo. The WHI Memory Study (WHIMS) was an ancillary to the WHI and investigated the effects of HT on risk of probable dementia and any cognitive impairment and on changes in global cognition over time. The WHI and ancillary WHIMS study were stopped earlier than planned for both the combination therapy (in 2002) and CEE-Alone (in 2004) because these treatments increased health risks and did not protect against coronary heart disease. Although study medications were discontinued, follow-up assessments continued. The purpose of the present contract is to continue prospective follow-ups, including dementia screening and cognitive assessments, of women in the WHIMS Epidemiology of Cognitive Health Outcomes (WHIMS-ECHO) cohort In addition, this contract continues prospective cognitive assessments in the more recently initiated Women's Health Initiative Memory Study of Younger Women (WHIMS-Y) to determine the long-term impact of random assignment to postmenopausal HT among women who were 50-54 years of age at the time they were randomized in the WHI hormone trials. WHIMS-Y tests the ¿window of opportunity¿ hypothesis that HT shortly after menopause will confer benefit to later cognitive health.